| Literature DB >> 35334548 |
Rasha A Mohamed1, El Sayed H Mohamed2, Mohamed A Basiouny3, Ibrahim M Hamoda4, El Sayed M Hanoura5, Elbadawy I Elhenedi6, Abd El Aziz A Sherief7.
Abstract
Background andEntities:
Keywords: action potentials; fatigue; muscle weakness; myasthenia gravis; quality of life; respiratory insufficiency
Mesh:
Year: 2022 PMID: 35334548 PMCID: PMC8955821 DOI: 10.3390/medicina58030374
Source DB: PubMed Journal: Medicina (Kaunas) ISSN: 1010-660X Impact factor: 2.430
Figure 1Flow chart of the study design.
Patients’ characteristics.
| Group A | Group B | ||
|---|---|---|---|
| Mean ± SD | Mean ± SD | ||
|
| 14.20 ± 1.01 | 14.46 ± 1.06 | 0.48 |
|
| 54.73 ± 3.34 | 55.02 ± 3.02 | 0.81 |
|
| 157.13 ± 2.82 | 158.46 ± 2.74 | 0.20 |
|
| 22.16 ± 1.07 | 21.89 ± 0.83 | 0.46 |
|
| |||
| Females | 12 (80%) | 13 (87%) | 0.62 |
| Males | 3 (20%) | 2 (13%) | |
|
| |||
| Grade IIA | 11 (73%) | 12 (80%) | 0.66 |
| Grade IIB | 4 (27%) | 3 (20%) |
BMI, Body mass index; SD, standard deviation; p-value, probability value.
Pulmonary function measures of pre- and post-treatment of both groups.
| Group A | Group B | |||
|---|---|---|---|---|
| Mean ± SD | Mean ± SD | MD | ||
|
| ||||
| Pre-treatment | 1.39 ± 0.08 | 1.38 ± 0.07 | 0.01 | 0.64 |
| Post-treatment | 1.54 ± 0.11 | 1.46 ± 0.07 | 0.08 | 0.02 * |
| MD (% of change) | 0.15 (10.8%) | 0.08 (5.8%) | ||
|
|
| |||
|
| ||||
| Pre-treatment | 1.28 ± 0.06 | 1.29 ± 0.07 | -0.01 | 0.60 |
| Post-treatment | 1.41 ± 0.08 | 1.34 ± 0.05 | 0.07 | 0.01 * |
| MD (% of change) | 0.13 (10.16) | 0.05 (3.88) | ||
|
|
| |||
|
| ||||
| Pre-treatment | 166.40 ± 1.84 | 165.46 ± 1.51 | 0.94 | 0.14 |
| Post-treatment | 179.53 ± 1.30 | 171.80 ± 1.08 | 7.73 | 0.001 * |
| MD (% of change) | 13.13 (7.89%) | 6.34 (3.83%) | ||
|
|
| |||
|
| ||||
| Pre-treatment | 43.26 ± 1.27 | 42.66 ± 1.23 | 0.60 | 0.20 |
| Post-treatment | 49.20 ± 1.32 | 47.13 ± 1.06 | 2.07 | 0.001 * |
| MD (% of change) | 5.94 (13.73%) | 4.47 (10.48%) | ||
|
|
|
FVC, forced vital capacity; FEV1, forced expiratory volume in one second; PEFR, peak expiratory flow rate; MVV, maximum voluntary ventilation; SD, standard deviation; MD, mean difference; p-value: probability value; * significant at p < 0.05.
CMAP amplitude, isometric muscle force, PedsQL TM MFS, PedsQL, and 6MWD of both groups.
| Group A | Group B | |||
|---|---|---|---|---|
| Mean ± SD | Mean ± SD | MD | ||
|
| ||||
| Pre-treatment | 4.13 ± 0.35 | 4.20 ± 0.41 | −0.07 | 0.63 |
| Post-treatment | 7.33 ± 0.72 | 5.93 ± 0.61 | 1.40 | 0.001 * |
| MD (% of change) | 3.2 (77.48%) | 1.73 (41.19%) | ||
|
|
| |||
|
| ||||
| Pre-treatment | 5.33 ± 1.11 | 5.20 ± 0.94 | 0.13 | 0.72 |
| Post-treatment | 7.46 ± 0.83 | 6.93 ± 1.09 | 0.53 | 0.14 |
| MD (% of change) | 2.13 (39.96) | 1.73 (33.27) | ||
|
|
| |||
|
| ||||
| Pre-treatment | 12.20 ± 0.86 | 11.80 ± 0.77 | 0.40 | 0.19 |
| Post-treatment | 18.73 ± 1.22 | 18.20 ± 1.08 | 0.53 | 0.21 |
| MD (% of change) | 6.53 (53.52%) | 6.40 (54.24%) | ||
|
|
| |||
|
| ||||
| Pre-treatment | 22.93 ± 0.96 | 22.73 ± 0.79 | 0.2 | 0.54 |
| Post-treatment | 30. 60 ± 1.05 | 26.60 ± 1.29 | 4 | 0.001 * |
| MD (% of change) | 7.67 (33.45%) | 3.87 (17.03%) | ||
|
|
| |||
|
| ||||
| Pre-treatment | 70.86 ± 0.91 | 70.40 ± 0.73 | 0.46 | 0.13 |
| Post-treatment | 77.80 ± 0.86 | 74.33 ± 0.72 | 3.47 | 0.001 * |
| MD (% of change) | 6.94 (9.79%) | 3.93 (5.58%) | ||
|
|
| |||
|
| ||||
| Pre-treatment | 66.86 ± 0.91 | 66.53 ± 0.51 | 0.33 | 0.23 |
| Post-treatment | 77.33 ± 0.48 | 71.60 ± 0.51 | 5.73 | 0.001 * |
| MD (% of change) | 10.47 (15.66%) | 5.07 (7.62%) | ||
|
|
| |||
|
| ||||
| Pre-treatment | 311.46 ± 2.35 | 310.66 ± 2.58 | 0.80 | 0.38 |
| Post-treatment | 350 ± 2.36 | 330.73 ± 2.65 | 19.27 | 0.001 * |
| MD (% of change) | 38.54 (12.37%) | 20.07 (6.46%) | ||
|
|
| |||
CMAP, compound motor action potential; MD, mean difference; p-value, probability value; PedsQL, pediatric Quality of Life; PedsQL TM MFS: pediatric quality of life inventory multidimensional fatigue scale; p-value, probability value; 6MWD, six-minute walk distance; SD, standard deviation; * significant at p < 0.05.
Mean stability indices of both groups.
| Group A | Group B | |||
|---|---|---|---|---|
| Mean ± SD | Mean ± SD | MD | ||
|
| ||||
| Pre-treatment | 1.57 ± 0.08 | 1.54 ± 0.09 | 0.03 | 0.31 |
| Post-treatment | 1.04 ± 0.05 | 1.40 ± 0.09 | −0.36 | 0.001 * |
| MD (% of change) | 0.53 (33.76%) | 0.14 (9.09%) | ||
|
|
| |||
|
| ||||
| Pre-treatment | 1.80 ± 0.07 | 1.76 ± 0.09 | 0.04 | 0.31 |
| Post-treatment | 1.17 ± 0.11 | 1.56 ± 0.06 | −0.39 | 0.001 * |
| MD (% of change) | 0.63 (35%) | 0.20 (11.36%) | ||
|
|
| |||
|
| ||||
| Pre-treatment | 1.97 ± 0.09 | 1.96 ± 0.12 | 0.01 | 0.87 |
| Post-treatment | 1.37 ± 0.07 | 1.64 ± 0.09 | −0.27 | 0.001 * |
| MD (% of change) | 0.60 (30.46%) | 0.32 (16.33%) | ||
|
|
|
APSI: anterior–posterior stability index; MLSI: medial–lateral stability index; MD, mean difference; OSI: overall stability index; p-value, probability value; SD, standard deviation; * significant at p < 0.05.